Literature DB >> 9098655

Drug interactions with proton pump inhibitors.

P Unge1, T Andersson.   

Abstract

Omeprazole, lansoprazole and pantoprazole are all mainly metabolised by the polymorphically expressed cytochrome P450 (CYP) isoform CYP2C19 (S-mephenytoin hydroxylase). All 3 proton pump inhibitors have a very limited potential for drug interactions at the CYP level. Small effects on CYP reported for these compounds are usually of no clinical relevance. No dose related adverse effects have been identified, suggesting that the small proportion of slow metabolisers is at no additional risk for clinically important drug interactions. The absorption of some compounds, e.g. benzylpenicillin (penicillin G), are altered during treatment with proton pump inhibitors as a result of the increased intragastric pH. A synergy has been confirmed between omeprazole and amoxicillin or clarithromycin in the antibacterial effect against Helicobacter pylori.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9098655     DOI: 10.2165/00002018-199716030-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  91 in total

1.  Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes.

Authors:  V Kerlan; Y Dreano; J P Bercovici; P H Beaune; H H Floch; F Berthou
Journal:  Biochem Pharmacol       Date:  1992-11-03       Impact factor: 5.858

Review 2.  Cytochrome P450: evolution and functional diversity.

Authors:  D W Nebert; R A McKinnon
Journal:  Prog Liver Dis       Date:  1994

Review 3.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

4.  Effects of ranitidine and sucralfate on ketoconazole bioavailability.

Authors:  S C Piscitelli; T F Goss; J H Wilton; D T D'Andrea; H Goldstein; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

5.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.

Authors:  K Chiba; K Kobayashi; K Manabe; M Tani; T Kamataki; T Ishizaki
Journal:  J Pharmacol Exp Ther       Date:  1993-07       Impact factor: 4.030

Review 6.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

7.  Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.

Authors:  T Andersson; J O Miners; M E Veronese; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

8.  Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe.

Authors:  L S Kaminsky; S M de Morais; M B Faletto; D A Dunbar; J A Goldstein
Journal:  Mol Pharmacol       Date:  1993-02       Impact factor: 4.436

9.  Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.

Authors:  K L Rost; H Brösicke; J Brockmöller; M Scheffler; H Helge; I Roots
Journal:  Clin Pharmacol Ther       Date:  1992-08       Impact factor: 6.875

10.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

Authors:  T Andersson; J O Miners; M E Veronese; W Tassaneeyakul; W Tassaneeyakul; U A Meyer; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

View more
  8 in total

Review 1.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

2.  Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy.

Authors:  Shan Cao; Gan Zhou; Dong-sheng Ou-Yang; Hui-zi Wu; Kui Xiao; Yao Chen; Dong Guo; Lan Fan; Zhi-rong Tan; Hai-tang Hu; Xiang-hong Qin; Hong-hao Zhou; Wei Zhang
Journal:  Acta Pharmacol Sin       Date:  2012-07-23       Impact factor: 6.150

Review 3.  Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions.

Authors:  D A Flockhart; Z Desta; S K Mahal
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

Review 4.  Drug-drug interaction profiles of proton pump inhibitors.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

Review 5.  The role of proton pump inhibitors in gastro-oesophageal reflux disease.

Authors:  Roy Dekel; Chad Morse; Ronnie Fass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

7.  A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications.

Authors:  Divya Patel; Richard Bertz; Song Ren; David W Boulton; Mats Någård
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

8.  Role of cytochrome P450 in drug interactions.

Authors:  Zakia Bibi
Journal:  Nutr Metab (Lond)       Date:  2008-10-18       Impact factor: 4.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.